Amy K Mottl, Andrew S Bomback, Laura H Mariani, Gaia Coppock, J Charles Jennette, Salem Almaani, Debbie S Gipson, Sara Kelley, Jason Kidd, Louis-Philippe Laurin, Krzysztof Mucha, Andrea Oliverio, Matthew Palmer, Dana Rizk, Neil Sanghani, M Barry Stokes, Katalin Susztak, Shikha Wadhwani, Cynthia C Nast
Glomerular diseases (GDs) represent the third leading cause of end-stage kidney disease (ESKD) in the US Diabetes was excluded from the CureGN Study, an NIH/NIDDK-sponsored observational cohort study of four leading primary GDs: IgA nephropathy (IgAN), membranous nephropathy (MN), focal segmental glomerulosclerosis (FSGS), and minimal change disease (MCD). CureGN-Diabetes, an ancillary study to CureGN, seeks to understand how diabetes influences the diagnosis, treatment, and outcomes of GD. It is a multicenter, prospective cohort study, targeting an enrollment of 300 adults with prevalent type 1 or type 2 diabetes and MCD, FSGS, MN, or IgAN, with first kidney biopsy obtained within 5 years of enrollment in 80% (20% allowed if biopsy after 2010)...
2023: Glomerular diseases